PLN inhibition and SERCA2a activation are known to show beneficial effects on cardiac function and hypertrophy in various HF models [17–19], and increase contractility in the cardiomyocytes isolated from heart failure patients [30], although there are few reports with respect to improvement of HF mortality [28, 29]. The gene discussed is PLN; the disease is hydrops fetalis.